Cancer Institute A national cancer institute
designated cancer center

Neyssa Marina

Publication Details

  • Children's Oncology Group's 2013 blueprint for research: Bone tumors PEDIATRIC BLOOD & CANCER Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N. 2013; 60 (6): 1009-1015


    In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.

    View details for DOI 10.1002/pbc.24429

    View details for Web of Science ID 000317934800030

    View details for PubMedID 23255238

Stanford Medicine Resources:

Footer Links: